 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

American Trust bought a new position in shares of Geron Co. (NASDAQ:GERN  Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The...

American Trust Invests $27,000 in Geron Co. (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN  Get Free Report)s stock price traded up 4.3% during trading on Wednesday . The stock traded as high as $2.41 and last traded at $2.40. 576,316 shares traded...

Geron (NASDAQ:GERN) Shares Up 4.3%

The Goldman Sachs Group upgraded shares of Geron (NASDAQ:GERN  Free Report) from a neutral rating to a buy rating in a research report sent to investors on Tuesday, MarketBeat.com reports. The...

Geron (NASDAQ:GERN) Rating Increased to Buy at The Goldman Sachs Group

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Geron upgraded to Buy from Neutral at Goldman Sachs

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and...

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

Logos Global Management LP lessened its holdings in shares of Geron Co. (NASDAQ:GERN  Free Report) by 11.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 3,550,000...

Geron Co. (NASDAQ:GERN) Shares Sold by Logos Global Management LP

Geron added to Best Ideas List at Wedbush

In a report released yesterday, Robert Driscoll from Wedbush reiterated a Buy rating on Geron (GERN Research Report), with a price target of $6.0... In a report released yesterday, Robert Driscoll from Wedbush reiterated a Buy rating on Geron (GERN &#8211...

Wedbush Keeps Their Buy Rating on Geron (GERN)

Geron (NASDAQ:GERN  Get Free Report)s stock had its outperform rating restated by research analysts at Wedbush in a research report issued to clients and investors on...

Wedbush Reaffirms Outperform Rating for Geron (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN  Get Free Report) Director Elizabeth G. Ofarrell acquired 6,607 shares of the businesss stock in a transaction that occurred on Thursday, August 24th. The...

Insider Buying: Geron Co. (NASDAQ:GERN) Director Buys 6,607 Shares of Stock

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Watchers	20,322
52-Wk Low	$1.95
52-Wk High	$3.84

Market Cap	$1.13B
Volume (M)	4.12M
52-Wk High	$3.84
52-Wk Low	$1.95

GERN Geron Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals